A citation-based method for searching scientific literature


List of co-cited articles
332 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
Bruce W Bode, Joseph A Johnson, Liselotte Hyveled, Søren C Tamer, Marek Demissie. Diabetes Technol Ther 2017
45
51

Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).
David Russell-Jones, Bruce W Bode, Christophe De Block, Edward Franek, Simon R Heller, Chantal Mathieu, Athena Philis-Tsimikas, Ludger Rose, Vincent C Woo, Anne Birk Østerskov,[...]. Diabetes Care 2017
93
43



Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes.
Eric Zijlstra, Marek Demissie, Tina Graungaard, Tim Heise, Leszek Nosek, Bruce Bode. J Diabetes Sci Technol 2018
27
55

A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5).
David C Klonoff, Mark L Evans, Wendy Lane, Hans-Peter Kempe, Eric Renard, J Hans DeVries, Tina Graungaard, Agon Hyseni, Theis Gondolf, Tadej Battelino. Diabetes Obes Metab 2019
34
44


Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus.
Maryam Fath, Thomas Danne, Torben Biester, Lars Erichsen, Olga Kordonouri, Hanne Haahr. Pediatr Diabetes 2017
32
40


Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial.
Keith Bowering, Christopher Case, John Harvey, Michael Reeves, Michael Sampson, Robert Strzinek, Ditte-Marie Bretler, Rikke Beck Bang, Bruce W Bode. Diabetes Care 2017
53
25

Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.
Chantal Mathieu, Bruce W Bode, Edward Franek, Athena Philis-Tsimikas, Ludger Rose, Tina Graungaard, Anne Birk Østerskov, David Russell-Jones. Diabetes Obes Metab 2018
47
25

Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide.
Jonas Kildegaard, Stephen T Buckley, Rasmus H Nielsen, Gro K Povlsen, Torben Seested, Ulla Ribel, Helle B Olsen, Svend Ludvigsen, Claus B Jeppesen, Hanne H F Refsgaard,[...]. Pharm Res 2019
39
30

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.
Tadej Battelino, Thomas Danne, Richard M Bergenstal, Stephanie A Amiel, Roy Beck, Torben Biester, Emanuele Bosi, Bruce A Buckingham, William T Cefalu, Kelly L Close,[...]. Diabetes Care 2019
934
20

Home Use of an Artificial Beta Cell in Type 1 Diabetes.
H Thabit, M Tauschmann, J M Allen, L Leelarathna, S Hartnell, M E Wilinska, C L Acerini, S Dellweg, C Benesch, L Heinemann,[...]. N Engl J Med 2015
270
18

Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial.
Klemen Dovc, Claudia Piona, Gül Yeşiltepe Mutlu, Natasa Bratina, Barbara Jenko Bizjan, Dusanka Lepej, Revital Nimri, Eran Atlas, Ido Muller, Olga Kordonouri,[...]. Diabetes Care 2020
38
23

Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3).
Helena W Rodbard, Devjit Tripathy, Maricela Vidrio Velázquez, Marek Demissie, Søren C Tamer, Milivoj Piletič. Diabetes Obes Metab 2017
31
25

Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial.
John B Buse, Anders L Carlson, Mitsuhisa Komatsu, Ofri Mosenzon, Ludger Rose, Bo Liang, Kristine Buchholtz, Hiroshi Horio, Takashi Kadowaki. Diabetes Obes Metab 2018
29
27

State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018.
Nicole C Foster, Roy W Beck, Kellee M Miller, Mark A Clements, Michael R Rickels, Linda A DiMeglio, David M Maahs, William V Tamborlane, Richard Bergenstal, Elizabeth Smith,[...]. Diabetes Technol Ther 2019
724
16

Moving toward the ideal insulin for insulin pumps.
Eda Cengiz, Bruce Bode, Michelle Van Name, William V Tamborlane. Expert Rev Med Devices 2016
19
36

Ultrafast-acting insulins: state of the art.
Lutz Heinemann, Douglas B Muchmore. J Diabetes Sci Technol 2012
59
14

A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus.
Tim Heise, Ulrike Hövelmann, Eric Zijlstra, Kirstine Stender-Petersen, Jacob Bonde Jacobsen, Hanne Haahr. Drugs Aging 2017
18
38

Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.
Tim Heise, Kirstine Stender-Petersen, Ulrike Hövelmann, Jacob Bonde Jacobsen, Leszek Nosek, Eric Zijlstra, Hanne Haahr. Clin Pharmacokinet 2017
37
18

Exercise management in type 1 diabetes: a consensus statement.
Michael C Riddell, Ian W Gallen, Carmel E Smart, Craig E Taplin, Peter Adolfsson, Alistair N Lumb, Aaron Kowalski, Remi Rabasa-Lhoret, Rory J McCrimmon, Carin Hume,[...]. Lancet Diabetes Endocrinol 2017
356
14

Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes.
Grit Andersen, Grégory Meiffren, Daniela Lamers, J Hans DeVries, Aymeric Ranson, Cyril Seroussi, Bertrand Alluis, Martin Gaudier, Olivier Soula, Tim Heise. Diabetes Obes Metab 2018
25
28

BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study.
Tim Heise, Grégory Meiffren, Bertrand Alluis, Cyril Seroussi, Aymeric Ranson, Jorge Arrubla, José Correia, Martin Gaudier, Olivier Soula, Rémi Soula,[...]. Diabetes Obes Metab 2019
22
31

The challenges of achieving postprandial glucose control using closed-loop systems in patients with type 1 diabetes.
Véronique Gingras, Nadine Taleb, Amélie Roy-Fleming, Laurent Legault, Rémi Rabasa-Lhoret. Diabetes Obes Metab 2018
47
14

Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics.
Paolo Pozzilli, Tadej Battelino, Thomas Danne, Roman Hovorka, Przemyslawa Jarosz-Chobot, Eric Renard. Diabetes Metab Res Rev 2016
70
12

Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.
Kellee M Miller, Nicole C Foster, Roy W Beck, Richard M Bergenstal, Stephanie N DuBose, Linda A DiMeglio, David M Maahs, William V Tamborlane. Diabetes Care 2015
835
12

Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus.
Marie L Misso, Kristine J Egberts, Matthew Page, Denise O'Connor, Jonathan Shaw. Cochrane Database Syst Rev 2010
291
12

Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes.
Erin Cobry, Kim McFann, Laurel Messer, Victoria Gage, Brandon VanderWel, Lauren Horton, H Peter Chase. Diabetes Technol Ther 2010
79
12

Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus.
Birgit Fullerton, Andrea Siebenhofer, Klaus Jeitler, Karl Horvath, Thomas Semlitsch, Andrea Berghold, Johannes Plank, Thomas R Pieber, Ferdinand M Gerlach. Cochrane Database Syst Rev 2016
39
15


Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial.
Bruce W Bode, Violeta Iotova, Margarita Kovarenko, Lori M Laffel, Paturi V Rao, Srikanth Deenadayalan, Magnus Ekelund, Steffen Falgreen Larsen, Thomas Danne. Diabetes Care 2019
18
33


Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries.
Jennifer L Sherr, Julia M Hermann, Fiona Campbell, Nicole C Foster, Sabine E Hofer, Jeremy Allgrove, David M Maahs, Thomas M Kapellen, Naomi Holman, William V Tamborlane,[...]. Diabetologia 2016
150
10

A review of a family of ultra-rapid-acting insulins: formulation development.
Alan Krasner, Roderike Pohl, Patrick Simms, Philip Pichotta, Robert Hauser, Errol De Souza. J Diabetes Sci Technol 2012
26
19

Stability and performance of rapid-acting insulin analogs used for continuous subcutaneous insulin infusion: a systematic review.
David Kerr, Erik Wizemann, Jakob Senstius, Mette Zacho, Francisco Javier Ampudia-Blasco. J Diabetes Sci Technol 2013
36
13

Insulin glulisine: a faster onset of action compared with insulin lispro.
T Heise, L Nosek, H Spitzer, L Heinemann, E Niemöller, A D Frick, R H A Becker. Diabetes Obes Metab 2007
60
10

Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin.
Lutz Heinemann, Robert Baughman, Anders Boss, Marcus Hompesch. J Diabetes Sci Technol 2017
34
14


Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas.
Stuart A Weinzimer, Garry M Steil, Karena L Swan, Jim Dziura, Natalie Kurtz, William V Tamborlane. Diabetes Care 2008
327
10

Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart.
Ananda Basu, Thomas R Pieber, Ann K Hansen, Stefanie Sach-Friedl, Lars Erichsen, Rita Basu, Hanne Haahr. Diabetes Obes Metab 2018
19
26

Insulin analogues in type 1 diabetes mellitus: getting better all the time.
Chantal Mathieu, Pieter Gillard, Katrien Benhalima. Nat Rev Endocrinol 2017
91
10

Clinical review: Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections.
Mitra M Fatourechi, Yogish C Kudva, M Hassan Murad, Mohamed B Elamin, Claudia C Tabini, Victor M Montori. J Clin Endocrinol Metab 2009
128
10

Use of fast-acting insulin aspart in insulin pump therapy in clinical practice.
Mark Evans, Antonio Ceriello, Thomas Danne, Christophe De Block, J Hans DeVries, Marcus Lind, Chantal Mathieu, Kirsten Nørgaard, Eric Renard, Emma G Wilmot. Diabetes Obes Metab 2019
21
23

Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.
Firas H El-Khatib, Courtney Balliro, Mallory A Hillard, Kendra L Magyar, Laya Ekhlaspour, Manasi Sinha, Debbie Mondesir, Aryan Esmaeili, Celia Hartigan, Michael J Thompson,[...]. Lancet 2017
126
10


Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.
Martin Tauschmann, Hood Thabit, Lia Bally, Janet M Allen, Sara Hartnell, Malgorzata E Wilinska, Yue Ruan, Judy Sibayan, Craig Kollman, Peiyao Cheng,[...]. Lancet 2018
166
10

Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis.
Eleni Bekiari, Konstantinos Kitsios, Hood Thabit, Martin Tauschmann, Eleni Athanasiadou, Thomas Karagiannis, Anna-Bettina Haidich, Roman Hovorka, Apostolos Tsapas. BMJ 2018
192
10

Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes.
Stuart A Weinzimer, Jennifer L Sherr, Eda Cengiz, Grace Kim, Jessica L Ruiz, Lori Carria, Gayane Voskanyan, Anirban Roy, William V Tamborlane. Diabetes Care 2012
93
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.